Physician profile
Santosh Rane
NPI 1649371915
$10,946.29
in general payments reported to CMS, 2019-2025
28 companies · $554 in 2025
The $554 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,359 · 2020: $1,416 · 2021: $1,235 · 2022: $529 · 2023: $967 · 2024: $3,887 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Travel and Lodging: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.89 |
| Travel and Lodging | $1,995.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,967.69 | 2019-2024 | Aveir, Ensite, Cardiomems |
| Medtronic Vascular, INC. | $1,876.30 | 2019-2020 | |
| Boston Scientific Corporation | $1,842.57 | 2019-2025 | Watchman Flx, Farapulse, Versacross Access Solution |
| Medtronic, INC. | $1,034.08 | 2021-2025 | Na, Pulseselect, Venaseal |
| Zoll Respicardia, INC. | $352.81 | 2021 | |
| Cardiva Medical, INC. | $338.58 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $298.11 | 2020-2024 | Lifevest |
| Biosense Webster, INC. | $186.27 | 2019-2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $159.30 | 2021-2025 | Camzyos, Eliquis |
| Atricure, INC. | $157.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $134.49 | 2020-2023 | |
| Amgen INC. | $106.49 | 2021-2025 | Repatha |
| Axonics, INC. | $90.78 | 2022 | |
| Pfizer INC. | $67.73 | 2022-2025 | |
| Cardiofocus, INC. | $63.71 | 2023 | Heartlight System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $44.38 | 2024 | Arcalyst |
| Cvrx, INC. | $37.45 | 2023-2025 | Barostim Neo System |
| Catheter Precision INC. | $25.76 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.19 | 2023 | Jardiance |
| Abiomed | $17.99 | 2024 | Impella |
| Novo Nordisk INC | $17.56 | 2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $17.34 | 2020 | |
| Biotronik INC. | $15.62 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.50 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Merck Sharp & Dohme LLC | $13.99 | 2024 | Verquvo |
| Philips North America LLC | $13.82 | 2020 | |
| Cardiovascular Systems INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santosh Rane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.